Journal
FUTURE ONCOLOGY
Volume 5, Issue 4, Pages 543-557Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/FON.09.15
Keywords
angiogenesis inhibitors; immunotherapy; metastatic melanoma; novel therapeutics; tyrosine kinase inhibitors
Categories
Ask authors/readers for more resources
Metastatic malignant melanoma is an incurable disease with a median survival of 8.5 months and a probability of surviving 5 years after the diagnosis of less than 5%. To date, no systemic therapy has meaningfully changed these survival end points. Currently, in the USA the FDA has approved three agents for the treatment of metastatic melanoma: hydroxyurea, dacarbazine and interleukin-2, None of these have demonstrated a meaningfully prolonged survival of patients with metastatic melanoma. Therefore, a number of innovative therapeutic strategies have been pursued to improve outcomes, including immune therapy, tyrosine kinase inhibitors and angiogenesis inhibitors. Herein, we review some of the recent advances in novel therapeutic developments for the treatment of metastatic melanoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available